- Company
- Will Lixiana follow-ons take over the market?
- by Moon, sung-ho Apr 19, 2023 05:51am
- Activity in related markets has been rising due to the aftermath of the reimbursement approval for Transcatheter Aortic Valve Implantation (TAVI) that had been made last year. Pharmaceutical companies have been increasingly conducting activities to target the Non-vitamin K antagonist oral anticoagulant (NOAC) market. According to indu
- Company
- Dutasteride's market share is on the rise
- by Nho, Byung Chul Apr 19, 2023 05:50am
- The biggest advantage of solving the leakage problem is caused by the soft capsule shell rupture. In the dutasteride drug market, which has been growing mainly in capsule form, recently launched tablet-type products are gradually increasing sales. Based on UBIST, dutasteride tablets generated sales of 9.1 billion won last year from 200 milli
- Company
- Will Enhertu pass the fiscal barrier and be reimb in KOR?
- by Eo, Yun-Ho Apr 19, 2023 05:50am
- The reimbursement progress of the anticancer drug that received 50,000 consents in a national petition is gaining attention. According to industry sources, the reimbursement review data for Enhertu, AstraZeneca and Daiichi Sankyo’s HER2-directed antibody-drug conjugate (ADC), has been supplemented and submitted to the authorities on the
- Company
- Never-ending patent dispute over Galvus
- by Kim, Jin-Gu Apr 18, 2023 05:38am
- In a patent dispute over Galvus, a DPP-4 inhibitor-type diabetes treatment, Novartis received a dismissal from the Intellectual Property Tribunal. Apart from this trial decision, the Galvus patent dispute is expected to continue for some time. This is because the dispute between Novartis and the generic company regarding the extension of the
- Company
- Sales of Pfizer, Gilead, and MSD soared last year
- by Jung, Sae-Im Apr 18, 2023 05:37am
- Last year, Korean subsidiaries of multinational pharmaceutical companies made external growth in general. Pfizer Korea, MSD Korea, and Gilead Sciences Korea have enjoyed an increase in sales of COVID-19 vaccines and treatments. The high sales growth of new drugs such as Keytruda, Gardasil 9, and Prolia also contributed to the increase in sales.
- Company
- Mitsubishi and Sanofi signs agreement to sell Rilutek in KOR
- by Jung, Sae-Im Apr 18, 2023 05:36am
- On the 17th, Mitsubishi Tanabe Pharma announced that the company had signed a domestic marketing agreement with Sanofi Aventis Korea for Sanofi’s amyotrophic lateral sclerosis (ALS) treatment ‘Rilutek (riluzole)’ on the 12th. Rilutek is the first treatment for ALS approved by the US FDA. The drug is used to extend survival or delay t
- Company
- Pay attention to the animal drug market worth 3 trillion won
- by Nho, Byung Chul Apr 17, 2023 05:58am
- Traditional pharmaceutical bio companies are entering the companion animal medicine and feed market worth 2.5 trillion won, attracting attention as they seek new growth engines and external expansion. Yuhan Corporation, Daewoong Pharmaceutical, Donghwa Pharmaceutical, Dongkuk Pharmaceutical, Kwangdong Pharmaceutical, Ildong Pharmaceutical, a
- Company
- Will the leukemia ADC Mylotarg be reimb this time?
- by Eo, Yun-Ho Apr 17, 2023 05:58am
- whether the new drug for acute myeloid leukemia (AML), ‘Mylotarg’ will be reimbursed in its second attempt is gaining attention. Mylotarg (gemtuzumab ozogamicin), which submitted an application for reimbursement listing earlier this year, is likely to be presented to the Cancer Disease Review Committee of the Health Insurance Review and
- Company
- Sales of cepha antibiotics make a rebound
- by Kim, Jin-Gu Apr 14, 2023 05:49am
- Biopharmaceutical companies that produce the so-called ‘cepha antibiotics' have taken a breather with the increased demand for related products due to the rapid increase in confirmed COVID-19 cases last year. This is in stark contrast to the situation of the previous year when many companies were contemplating whether to withdraw their ce
- Company
- “Reimb standard for hemophilia should align with approvals"
- by Jung, Sae-Im Apr 14, 2023 05:49am
- The Korean Society of Hematology has set out to narrow the gap between the approved indication and reimbursement standards for hemophilia treatments. Through the amendment, KSH aims to apply the optimal dose and dosing schedule for each patient as personalized treatment strategies have settled as the standard for maintenance and prevention t
